Evaluating the safety of a rotavirus vaccine: The REST of the story

Clinical Trials

Volumn 5, Issue 2, 2008, Pages 131-139

  Heyse, Joseph F ^a   Kuter, Barbara J ^a   Dallas, Michael J ^a   Heaton, Penny ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NOVAVAX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROENTERITIS; HEALTH CARE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VACCINATION; VIRUS INFECTION;

HUMANS; INFANT; INTUSSUSCEPTION; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; ROTAVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 43649093883     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774508090507     Document Type: Article

References (22)

1. Parashar UD, Hummelmann EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9: 565-72.
2. Bresee JS, Glass RJ, Ivanoff B, Gentsch JR. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999; 17: 2207-22.
3. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1999; 48(RR-2): 1-20.
4. Saez-Llorens X, Nieto Guevara J. Intussusception and rotavirus vaccines: what is the background risk? Ped Infect Dis J 2004; 23(4): 363-65.
5. Intussusception among recipients of rotavirus vaccine - United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999; 48: 577-81.
6. Kramarz P, France EK, Destefano F, et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J 2001; 204: 10-16.
7. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344(8): 564-72.
8. Parashar UD, Holman RC, Cummings KC, et al. Trends in intussusception-associated hospitalizations and deaths among US infants. Pediatrics 2000; 106: 1413-21.
9. Rennels MB, Parashar UD, Holman RC, et al. Lack of an apparent association between intussusception and wild or vaccine rotavirus infection. Pediatr Infect Dis J 1998; 17: 924-25.
10. Haber P, Chen RT, Zanardi LR, et al. An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone? Pediatrics 2004; 113(4): 3353-59.
11. Joensuu J, Koskenniemi E, Pang XL, Vesikari T. Randomized placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; 350: 1205-09.
12. Joensuu J, Koskenniemi E, Vesikari T. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants. Pediatr Infect Dis J 1998; 17: 334-40.
13. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus human reassortant rotavirus vaccines - report of the National Multicenter Trial: United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996; 97: 7-13.
14. Vesikari T, Clark HF, Offit PA, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 2006; 24: 4821-29.
15. Peter G, Myers MG. Intussusception, rotavirus and oral vaccines: summary of a workshop. Pediatrics 2002; 110(6): e67.
16. Glass RJ, Bresee JS, Parashar UD, et al. The future of rotavirus vaccines: a major setback leads to new opportunities. Lancet 2004; 363: 1547-50.
17. Heaton PM, Goveia MG, Miller JM, et al. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J Infect Dis 2005; 192 (Suppl 1): S17-S21.
18. Chang EJ, Zangwill KM, Lee H, et al. Lack of association between rotavirus infection and intussusception implications for use of attenuated rotavirus vaccines. Pediatr Infect Dis J 2002; 21: 97-102.
19. Uhnoo I, Riepenhoff-Talty M, Dharakul T, et al. Extramural spread and development of hepatitis in immunodeficient and normal mice infected with rhesus rotavirus. J Virol 1990; 64(1): 361-68.
20. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New Engl J Med 2006; 354: 23-33.
21. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Chapman and Hall/CRC, Boca Raton, FL, 2000.
22. Ellenberg SS, Foulkes MA, Midthun K, et al. Evaluating the safety of new vaccines: summary of a workshop. Am J Public Health 2005; 95(5): 800-07.